Single Institute Experience with the Use of ConPaS Technique for the Treatment of Head and Neck Cancer
DOI:
https://doi.org/10.12974/2309-6160.2014.02.01.2Keywords:
Head-neck, 3D based radiotherapy, Conpas, parotid sparing, survival, side effect.Abstract
Aim: In the complex therapy of head neck cancers modern 3D based radiotherapy plays an important role. The parotid sparing effect of intensity modulated radiotherapy is proven, but in many patients the conventional 3D based techniques are still being used. Since 2006 the “Conpas” technique has been routinely used in our institution for the treatment of locally advanced head neck tumor patients. The aim of our study was to analyze the dosimetry, survival and side effect profile of this 3D based treatment modality.
Patient and Methods: Between 01.07.2006 and 31.11.2008 a total of 83 patients were treated using this technique. An elective dose of 50,4 Gy was prescribed to the primary tumor and the bilateral neck node regions, followed by a simple two field boost to the primary tumor region (up to 70Gy). We retrospectively analyzed the following factors related to this method: dosimetry profile (PTV and OR doses, focusing on parotid gland doses), clinical responses, local and distant progression free survival profile, acute and late side effects.
Results: The mean dose of primary tumors was 71.98 Gy, the elective region dose of 50.4 Gy was achieved in all cases. Following the treatment in 37 patients complete clinical response in 25 cases partial response in 5 cases stable disease and in 16 cases progressive disease was registered. The mean overall survival was 30,06 months, the mean disease free survival was 25,82 months. When reporting the superficial lobe volumes in “lower” tumor locations good mean parotid doses were achieved (25.3 Gy and 23.4 Gy). Comparing the acute side effect profiles in the “upper” localized group higher rate of Grade III xerostomia (21% vs. 2%, p?0.05) and dermatitis (27% vs. 6%, p?0.05) were observed compared to “lower” localization group. In the “upper” localized group the late xerostomia (grade 2-3) rate was also higher (8% vs. 0%, p?0.05).
Conclusion: Based on our experience Conpas technique is feasible technique for treatment of advanced head neck cancer patients. Our clinical outcome, dosimetry and follow up results show that this technique should be used successfully in patients with ”lower” localized primer tumor sites. High attention should be addressed when reporting parotid doses.
References
Jeremic B, Milicic B, Dagovic A, et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22: 3540–8. http://dx.doi.org/10.1200/JCO.2004.10.076
Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081–6. http://dx.doi.org/10.1093/jnci/91.24.2081
Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:659–64. http://dx.doi.org/10.1016/j.ijrobp.2004.12.015
Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 2002;63:203–11. http://dx.doi.org/10.1016/S0167-8140(02)00013-0
Marsh L, Eisbruch A, Watson B, et al. Treatment planning for parotid sparing in the patient requiring bilateral neck irradiation. Med Dosim 1996;21:7–13. http://dx.doi.org/10.1016/0958-3947(95)02048-9
Huguenin P, Taussky D, Moe K, et al. Quality of life in patients cured from carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys 1999;45:47–52. http://dx.doi.org/10.1016/S0360-3016(99)00128-5
Wijers O, Levendag P, Braaksma M, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 2002;24:737–47. http://dx.doi.org/10.1002/hed.10129
Eisbruch A, Haken R ten, Kim H, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 45:577–87. http://dx.doi.org/10.1016/S0360-3016(99)00247-3
Eisbruch A, Kim H, Terrell J, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-andneck cancer. Int J Radiat Oncol Biol Phys 2001;50:695–704. http://dx.doi.org/10.1016/S0360-3016(01)01512-7
Lee N, Xia P, Quivey J, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12–22. http://dx.doi.org/10.1016/S0360-3016(02)02724-4
Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Published June 10, 2003.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-46. http://dx.doi.org/10.1016/0360-3016(95)00060-C
Wiggenraad R, Mast M, van Santvoort J, Hoogendoorn M, Struikmans H. ConPas: a 3-D conformal parotid glandsparing irradiation technique for bilateral neck treatment as an alternative to IMRT. Strahlenther Onkol. 2005; 181(10): 673-82. http://dx.doi.org/10.1007/s00066-005-1413-8
Gregoire V, Coche E, Cosnard G, et al. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardising terminology and procedure based on the surgical experience. Radiother Oncol 2000; 56: 135–50. http://dx.doi.org/10.1016/S0167-8140(00)00202-4
Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16. http://dx.doi.org/10.1016/S0360-3016(00)00663-5
Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-6. http://dx.doi.org/10.1093/jnci/91.24.2081
Huguenin P, Taussky D, Moe K, et al. Quality of life in patients cured from carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys 1999;45:47–52. http://dx.doi.org/10.1016/S0360-3016(99)00128-5
Bär W, Schwarz M, Alber M, et al. A comparison of forward and inverse treatment planning for intensity-modulated radiotherapy of head and neck cancer. Radiother Oncol 2003;69:251–8. http://dx.doi.org/10.1016/j.radonc.2003.08.002
Braaksma M, Wijers O, Sörnsen de Koste J van, et al. Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. Radiother Oncol 2003;66:291–302. http://dx.doi.org/10.1016/S0167-8140(03)00038-0
Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 2002;63:203–11. http://dx.doi.org/10.1016/S0167-8140(02)00013-0
Marsh L, Eisbruch A, Watson B, et al. Treatment planning for parotid sparing in the patient requiring bilateral neck irradiation. Med Dosim 1996;21:7–13. http://dx.doi.org/10.1016/0958-3947(95)02048-9
K.S. Clifford Chao (editor). Practical essentials of intensity modulated radiation therapy. Second edition. Lippincott Williams&Wilkins 2003:146. ISBN 0-7817-5279-5.
Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):981-91. http://dx.doi.org/10.1016/j.ijrobp.2006.06.013
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 Feb;12(2):127-36. Epub 2011 Jan 12.
Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, Nutting CM, PARSPORT Trial Management Group. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol (R Coll Radiol). 2007; 19(8): 604-13. Epub 2007 Aug 13. PMID: 17706404.
Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996; 36: 469-80. http://dx.doi.org/10.1016/S0360-3016(96)00264-7
Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873–79. http://dx.doi.org/10.1200/JCO.2007.11.5501
